Plasminogen activator Inhibitor 1 (PAI-1) inhibits plasminogen activators leading to decreased fibrinolysis and increased risk of thromboembolic disease (TED). Shifts in PAI-1 promoter genome from normal 5G>5G to 4G>5G or 4G>4G alleles are associated with overexpression of PAI-1. In this study patients with residual venous thrombi were observed to have increased PAI-1 levels and more frequent shifts to 4G alleles. Of the 26, 20 (76.9%) patients with unresolved thrombus had elevated PAI-1 values. 4G genomic shifts were found in 92.9% patients studied. Normal PAI-1 levels were found in 5 patients with 4G polymorphisms. Thus, PAI-1 is often elevated among patients with residual thrombus, with an unexpectedly high prevalence of the 4G polymorphism of the promoter genome. Patients with persistent thrombus should be considered at risk of having constituently increased PAI-1 due to genomic changes in the PAI-1 promoter genome. Hypotheses are proposed to explain those with normal PAI-1, despite having 4G polymorphisms.
Introduction
Fibrinolysis is the process wherein plasminogen activators tPA and uPA activate the zymogen plasminogen to its active serine protease plasmin, which then cleaves soluble fibrinogen and cross-linked fibrin clearing intravascular thrombi. Homeostatic balance of this system is maintained by a series of inhibitors. The tPA and uPA are suppressed by plasminogen activator inhibitor 1 (PAI-1). Alpha-2-antiplasmin inhibits plasmin. Thrombin activatable fibrinolysis inhibitor disrupts the binding of plasmin onto fibrin by cleaving the C-terminal lysine residue-binding site on fibrinogen. 1 When PAI-1 is functionally or constituently deficient, bleeding may occur due to inadequately suppressed fibrinolysis. [2] [3] [4] When there is excess PAI-1, the fibrinolytic capacity is decreased, leaving the patient at increased risk of thrombosis. [5] [6] [7] [8] [9] [10] Excess levels of PAI-1 can occur as an acute phase reactant mediated by inflammatory cytokines interleukin 1 (IL-1), transforming growth factor beta (TGF-b), tumor necrosis factor alpha (TNF-a), endotoxin, and low-density lipoprotein (LDL)like Lp(a) lipoprotein. 1, 6, [11] [12] [13] Excess levels of PAI-1 may also be due to alterations in its promoter 5G>5G genome which normally contains 2 alleles, with each containing 5 consecutive guanosine residues. A constitutive change in this genome causes individuals carrying 2 4G alleles (4G>4G) to have elevated levels of PAI-1, while individuals carrying 4G>5G alleles have intermediate levels, as compared to the basal levels of 5G/5G carriers. 7, 9, 10, 14, 15 Thus phenotypic expression of the 4G>4G and 4G>5G genomes could be a hypercoagulation syndrome wherein patients with elevated PAI-1 would have difficulty clearing intravascular thrombi. This is an observational study describing this scenario.
Methods
In our hospital patients planned for knee or hip joint arthroplasty and who have histories of thromboembolic disease (TED), including deep vein thrombosis (DVT) and pulmonary embolus (PE) are often examined preoperatively for evidence of a hypercoagulation syndrome. The hospital computerized laboratory records were probed for such patients who had had measurements of their PAI-1 and the 4G>5G genome as part of that hypercoagulation survey. The clinical records of these patients were then examined for their history of TED and for any repeat radiographic studies to determine whether the thrombus had resolved.
The PAI-1 activity was performed by Quest Diagnostics Nichols Institute San Juan Capistrano, CA, using a chromogenic assay (normal: males: 2.0-47.1 IU/mL; females: 2.0-40.7 IU/mL). 16 The 4G>5G polymorphism was assayed by Quest Diagnostics Nichols Institute using polymerase chain reaction (PCR) amplification of a portion of the promoter of the PAI-1 gene, followed by single primer extension and detection of fluorescent extension products on an automated DNA sequencer. 16
Results
A total of53 patients were found to have had measurements of their PAI-1 and/or its promoter genome. The indications for having these studies included family histories of hypercoagulation, 5 acute arterial thrombotic events, 5 thrombotic obstetrical complications, 2 and TED with DVT, PE, or both. 17 Among these 53 patients, 19 (35.8%) had normal PAI-1 levels (mean: 22.8 IU/mL, median: 22 IU/mL; range: 2-38 IU/mL) and 34 (64.1%) had elevated PAI-1 values (mean: 107.5 IU/mL, median: 92 IU/mL; range: 48 to >200 IU/mL). The PAI-1 promoter genome was assayed for 28 of these patients, and the 4G>5G polymorphism was found in 14 and the 4G>4G polymorphism was found in 12. Two had normal 5G>5G pattern.
Among the 41 patients who had histories of TED, 26 (63.4%) were found to have residual thrombus by ultrasound or chest computed tomography (CAT) scan angiogram (computed tomography angiography [CTA]) more than 1 month beyond the acute event. Of these 26 patients, there were 20 (76.9%) with elevated PAI-1 levels. Of the 15 patients with no residual venous thrombosis, 9 (60%) also had elevated PAI-1 levels. There was a tendency toward higher PAI-1 serum concentrations for those with residual thrombus (see Table 1 ).
From among the patients selected for these studies by the hematologists, there were 5 who had normal PAI-1 levels despite having 4G allelic shifts. These included 4 patients with homozygous 4G>4G alleles and 1 with the heterozygous 4G>5G pattern.
When examined from the prospective of the genomic patterns, residual thrombus was found in 1 of 1 with the normal 5G>5G pattern, in 8 of 12 with the 4G>5G heterozygous allele, and in 7 of 11 with the 4G>4G homozygous allele. One of the patients with 4G>4G pattern had normal PAI-1 level. There were no significant differences in the PAI-1 levels for those with 4G>4G and the 4G>5G genomes (see Table 2 ).
Of the 53 patients studied, a majority of 36 had 1 to 4 additional markers for hypercoagulation, including protein C deficiency, protein S deficiency, elevated homocysteine, methylenetetrahydrofolate reductase genome defect, factor V Leiden, prothrombin 20210 genome, lupus anticoagulant syndrome, or the antiphospholipid syndrome (data not shown). There was no clustering of these markers among the patients with shifts in the PAI-1 promoter genome.
Discussion
Some, but not all, studies found an increased risk for idiopathic, secondary or relapsed DVT among patients with the 4G>4G and 4G>5G polymorphisms. 7,8,10,18-24 A meta-analysis of polymorphisms found an increased odds ratio for DVT, when the 4G allele was present among patients with other genetic risk factors for hypercoagulation, but not among patients having acquired markers for hypercoagulation. 8 There also appears to be a linkage for DVT when these alleles were considered along with metabolic risk factors such as body mass index and serum levels of triglycerides, glucose level, and C-reactive protein. 10, 21, 22, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Patients with TED have an average 2 times higher PAI-1 activity and 40% higher antigen than did the controls, but they also had higher body mass index, lipid levels, fasting glucose, and insulin levels. There was no difference between patients and controls for the 4G and 5G alleles unless triglycerides levels were factored in. 10 Body mass increase may have a direct effect on PAI-1 levels, in that the PAI-1 increased 4-fold between the lowest and the highest BMI quartiles. 29 Increased levels of plasminogen inhibitors correlate with decreased fibrinolytic capacity. The 4G/4G and 4G/5G genotypes suppress global fibrinolytic activity as measured by the euglobulin lysis time, after 20 minutes of venous occlusion among patients with DVT. 15 Decreased global fibrinolytic capacity when coupled with measurements of PAI-1was a better etiologic expression for idiopathic DVT when compared to other predisposing factors. 34 The start of clot lysis can be detected 1 to 2 weeks following an acute DVT, with normalization of the involved veins by ultrasound analysis in 57% to 78% of the patients after 6 months. [35] [36] [37] As would be expected, there is an inverse relationship between percentage recanalization and PAI-1. 37 Patients with lower levels of PAI-1 on presentation and after 1 week had more frequent complete resolution of their DVT at 6 months. Those with high tPA had the best outcomes, irrespective of the PAI-1 level. 38, 39 Another element in this process involves the number of platelets in the clot and the platelet-derived PAI-1. 40, 41 Knowing the PAI-1 concentration may be important information when considering the optimal dose and duration of therapy of therapeutic tPA. The effectiveness of tPA was reduced when the PAI-1 was elevated. 17 A similar impediment to streptokinase was not found when assaying the 4G/5G polymorphism and insertion/deletion polymorphisms of tPA. 42 As herein reported there are individuals who have 4G>4G or 4G>5G promoter polymorphisms but with normal PAI-1 levels. This raises questions about other factors that may influence the phenotypic expression of the final product PAI-1. This pathway is clearly not linear. In vitro cell culture experiments have demonstrated mechanisms which stimulate and others that suppress this pathway. Hypotheses can be generated to explain these outcomes were any of these epigenetic factors coinherited in a defective manner with one of the 4G polymorphisms. As example, if the docking sites for one of these stimulatory epigenetic events were defective, there would be less PAI-1 produced.
Stimuli of the promoter gene transcription to its messenger RNA (mRNA) production and synthesis of PAI-1 have been described, including proto-oncogens c-Jun and c-Fas; growth factors epidermal growth factor (EGF), TGF-b, plateletderived growth factor (PDGF), TNF-a, thrombin, IL-1, and upstream stimulatory factor 1 (USF-1); and phosphodiesterace. [43] [44] [45] [46] [47] [48] [49] [50] [51] TGF-b not only increases PAI-1 mRNA but also increases its half-life by influencing the posttranscription clearance. 52 There is a glucocorticoid response element. 53 Salt intake influences the amount of PAI-1 made via the reninangiotensin-aldosterone system. 54 There are circadian variations which operate via the BMAL1 and BMAL2 heterodimers, which cause PAI-1 levels to be highest in the morning. 55, 56 Some of these influences are most apparent in those with 4G>4G genomic pattern.
Less is described regarding suppression of the 4G/5G promoter genome function. There is a step wherein the latent form of PAI-1 is converted to the active form. 57 What controls this is unknown. Forskolin by way of the adenylate cyclase activation suppresses mRNA production. 58, 59 Could there be an overexpression of this function among some patients with the 4G polymorphism?
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